Business context and reporting period
Filing identity differs from the request metadata: the supplied filing is Rosewind Corporation’s Form 10-Q, filed May 19, 2015, for the quarter and nine months ended March 31, 2015—not an Aytu BioPharma filing or a 2014 Q3 report. Before April 16, 2015, the financial statements reflect the combined historical results of Luoxis Diagnostics and Vyrix Pharmaceuticals. Rosewind subsequently merged with those companies; Ampio held 81.5% of Rosewind after the merger.
The business focused on developing and commercializing specialty healthcare products, including the RedoxSYS diagnostic system and Zertane, a drug candidate for premature ejaculation. The company reported no material revenue from operations.
Financial results and position
| Metric | Three months ended Mar. 31, 2015 | Nine months ended Mar. 31, 2015 | Comparison |
|---|---|---|---|
| Total revenue | $23,829 | $79,746 | $12,500 and $37,500, respectively, in 2014 |
| Operating expenses | $1,829,966 | $5,560,716 | $2,003,466 and $4,427,115, respectively, in 2014 |
| Net loss | $1,842,189 | $5,567,960 | $1,680,377 and $3,852,119, respectively, in 2014 |
| Net loss per share | $(0.04) | $(0.13) | $(0.04) and $(0.11), respectively, in 2014 |
| Cash used in operations | Not provided for the quarter | $4,846,450 | $3,729,866 used in the prior-year nine-month period |
License revenue was primarily amortization of prior upfront license payments; RedoxSYS product and service revenue was $2,400 for the quarter and $15,460 for the nine-month period. Gross margin is not clearly provided.
At March 31, 2015, cash was $1,491,202 (versus $2,639,650 at June 30, 2014), total assets were $10,201,465, total liabilities were $9,650,209, and stockholders’ equity was $551,256. Current liabilities included $8.0 million of notes payable to Ampio, versus $4.3 million at June 30, 2014. The filing’s balance-sheet figures imply a working-capital deficit of approximately $7.55 million, while its liquidity discussion reports $7.522 million; the figures do not reconcile. No material market risk exposure was reported.
Material changes versus prior comparable periods
- Nine-month revenue increased to $79,746 from $37,500, remaining immaterial relative to operating costs.
- Nine-month net loss increased to $5.57 million from $3.85 million. General and administrative expense rose to $2.99 million from $1.72 million, with management attributing the increase primarily to stock compensation and professional fees, including SEC-related legal expense.
- Nine-month research and development expense decreased to $2.42 million from $2.64 million, mainly reflecting lower clinical trial and sponsored research costs.
- Operating cash use rose to $4.85 million from $3.73 million; Ampio provided $3.7 million in financing during the period.
Outlook, risks, contingencies, and unusual items
- Management said Ampio provided $4 million after quarter-end and committed an additional $10 million before April 15, 2016. The filing says the funding was converted into Rosewind equity as of April 16, 2015; subsequent-event disclosures also describe the $10 million as a promissory note issued by Ampio in the merger. Verify the final form and terms of the financing.
- Management believed available funding would support operations into the second half of 2016, and stated it believed the company could continue as a going concern through June 30, 2016. This depended on funding and operating assumptions that could prove incorrect. The company planned to seek additional capital and reported an expected average cash burn of $400,000–$500,000 per month for fixed and ongoing costs, before additional development and commercialization spending.
- Management expected RedoxSYS research collaborations to continue through 2015 and anticipated RedoxSYS sales revenue during 2015 and 2016. It described Zertane as in late-stage development, with a potential U.S. NDA and marketing in the second half of 2016 if development succeeded. These are forward-looking expectations, not assurances.
- Commitments totaled $1.876 million, including $388,000 for clinical research and trials, $298,000 under a related-party sponsored research agreement, and $1.122 million in management fees. The filing reported no material pending legal proceedings and no material changes to previously disclosed risk factors.
- Key risks include dependence on financing and Ampio, clinical and regulatory outcomes, commercialization and partnership execution, intellectual property, and the possibility that funding could run out sooner than expected. The filing states that insufficient financing could force delays, reductions, or termination of development or commercialization efforts.
Important facts for investors to verify
- Confirm the issuer, reporting period, and accounting scope: this is Rosewind’s March 2015 10-Q, with historical results for Luoxis and Vyrix, not an Aytu BioPharma 2014 Q3 filing.
- Reconcile the reported $7.522 million working-capital deficit with the balance-sheet amounts, which indicate approximately $7.55 million.
- Verify the amount, timing, and legal form of Ampio’s post-quarter funding and the merger-related debt cancellations and promissory note.
- Assess liquidity against the stated $400,000–$500,000 monthly fixed-cost burn, additional development spending, and the company’s reliance on future financing.
- Track clinical, regulatory, and commercial milestones for Zertane and RedoxSYS, and whether projected product revenue materialized.